Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial

PROSTATE CANCER Clinical Trial

Official title:

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06040125
• Other study ID #: 23-109
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2024
• Est. completion date: February 28, 2027

Study information

• Verified date: February 2024
• Source: Dana-Farber Cancer Institute
• Contact: Christina Dieli-Conwright, MD
• Phone: 617-582-8321
• Email: ChristinaM_Dieli-Conwright[@]dfci.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a 16-week supervised, clinic-based circuit training intervention utilizing resistance and functional exercises and self-directed aerobic exercise will improve frailty and sarcopenic status and disease progression outcomes among pre-frail/frail metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). The names of the study intervention involved in this study is: • Supervised circuit training (aerobic and resistance exercise regimen)

Description:

This research study is a pilot, randomized control study, which is the first-time investigators are examining this intervention in this setting. Participants will be randomized into one of two study groups: Exercise Group versus Attention Control Group. Randomization means a participant is placed into a group by chance. The research study procedures include screening for eligibility, study treatment, including extensive evaluations of fitness, physical health and strength, blood tests, muscle biopsy, surveys, and follow-up visits. Participation in this research study is expected to last about 16 weeks. It is expected that about 80 people will take part in this research study. The Prostate Cancer Foundation is providing funding for this research study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: February 28, 2027
• Est. primary completion date: February 28, 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability to understand and the willingness to sign informed consent prior to any study-related procedures.
• Diagnosed with metastatic prostate cancer.
• Aged =18 years; due to the rarity of the disease in those <18 years, this age bracket will not be included.
• Have been receiving androgen deprivation (either with or without androgen receptor targeted treatment) for at least one month and expect to remain on their treatment for at least 4 months.
• Are pre-frail or frail as indicated by the FRAIL scale (a score of 1-2 = pre-frail; 3-5 = frail).
• Have physician's clearance to participate in exercise.
• Speak English.
• Participate in less than 2 structured resistance exercise sessions per week over the last 4 months.
• Participate in less than or equal to 60 minutes of moderate-to-vigorous aerobic exercise per week over the last month.
• Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.

Exclusion Criteria:

• Receiving chemotherapy. This study is exclusively targeting androgen deprivation therapy-related effects.
• Have unstable bone lesions. In general patients with severely symptomatic/unstable bone lesions due to bone metastases are at a higher risk of fractures.
• Complete 2 or more structured resistance exercise sessions per week over the last 4 months and participate in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current exercise program.
• Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded.
• Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting androgen deprivation therapy-related effects.
• Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study.

Related Conditions & MeSH terms

• Frailty
• Metastatic Prostate Cancer
• Metastatic Prostate Carcinoma
• PROSTATE CANCER
• Prostatic Neoplasms
• Sarcopenia

Intervention

Behavioral:
• Supervised Circuit Training
16-week, multicomponent exercise intervention comprised of sessions supervised by certified exercise oncology trainer and home-based, self-directed aerobic exercises. Stationary bike and accelerometer (activity/heart rate monitor) will be provided.

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	Dana-Farber Cancer Institute	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Prostate Cancer Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Circulating Inflammation for Exercise Group	Assessed by change in systemic inflammatory biomarkers through blood analysis (ul/ml).	Baseline (week 0) and Post-intervention (week 17)
Primary	Frailty	This will be assessed by the Fried Frailty Phenotype, which measures participant ratings on a five-characteristic scale and will be totaled for an overall frailty score of 1-2, identified as prefail, or =3, identified as frail. Participants will receive a score of 1 (experience characteristic) or 0 (do not experience) for each characteristic.	Baseline (week 0) and Post-intervention (week 17)
Secondary	Sarcopenia	A sarcopenia score of =10.75 kg/m2, as assessed by computed tomography (CT), will be the cut point used for identifying muscle loss = 1 point.	Baseline (week 0) and Post-intervention (week 17)
Secondary	Skeletal Muscle Biomarkers - myokines	Assessed from muscle biopsy specimens of the vastus lateralis (ul/ml).	Baseline (week 0) and Post-intervention (week 17)